دورية أكاديمية
أعرض في EDS

Using 3D-bioprinted models to study pediatric neural crest-derived tumors.

التفاصيل البيبلوغرافية
العنوان: Using 3D-bioprinted models to study pediatric neural crest-derived tumors.
المؤلفون: Quinn CH; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA., Beierle AM; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, 35205, USA., Julson JR; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA., Erwin ME; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA., Alrefai H; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, 35205, USA., Markert HR; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA., Stewart JE; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA., Hutchins SC; Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35233, USA., Bownes LV; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA., Aye JM; Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35233, USA., Mroczek-Musulman E; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA., Hicks PH; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA., Yoon KJ; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA., Willey CD; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, 35205, USA., Beierle EA; Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, 35205, USA.; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, 35205, USA.; Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
المصدر: International journal of bioprinting [Int J Bioprint] 2023 Mar 29; Vol. 9 (4), pp. 723. Date of Electronic Publication: 2023 Mar 29 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: ACCScience Publishing Country of Publication: Singapore NLM ID: 101709763 Publication Model: eCollection Cited Medium: Internet ISSN: 2424-8002 (Electronic) Linking ISSN: 24248002 NLM ISO Abbreviation: Int J Bioprint Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2023- : Singapore : ACCScience Publishing
Original Publication: Singapore : Whioce Publishing Pte. Ltd., [2015]-
مستخلص: The use of three-dimensional (3D) bioprinting has remained at the forefront of tissue engineering and has recently been employed for generating bioprinted solid tumors to be used as cancer models to test therapeutics. In pediatrics, neural crest-derived tumors are the most common type of extracranial solid tumors. There are only a few tumor-specific therapies that directly target these tumors, and the lack of new therapies remains detrimental to improving the outcomes for these patients. The absence of more efficacious therapies for pediatric solid tumors, in general, may be due to the inability of the currently employed preclinical models to recapitulate the solid tumor phenotype. In this study, we utilized 3D bioprinting to generate neural crest-derived solid tumors. The bioprinted tumors consisted of cells from established cell lines and patient-derived xenograft tumors mixed with a 6% gelatin/1% sodium alginate bioink. The viability and morphology of the bioprints were analyzed via bioluminescence and immunohisto chemistry, respectively. We compared the bioprints to traditional twodimensional (2D) cell culture under conditions such as hypoxia and therapeutics. We successfully produced viable neural crest-derived tumors that retained the histology and immunostaining characteristics of the original parent tumors. The bioprinted tumors propagated in culture and grew in orthotopic murine models. Furthermore, compared to cells grown in traditional 2D culture, the bioprinted tumors were resistant to hypoxia and chemotherapeutics, suggesting that the bioprints exhibited a phenotype that is consistent with that seen clinically in solid tumors, thus potentially making this model superior to traditional 2D culture for preclinical investigations. Future applications of this technology entail the potential to rapidly print pediatric solid tumors for use in high-throughput drug studies, expediting the identification of novel, individualized therapies.
Competing Interests: The authors declare no conflict of interests.
(Copyright: © 2023, Quinn CH, Beierle AM, Julson JR, et al.)
References: Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-6. (PMID: 12011461)
Cells. 2020 Mar 11;9(3):. (PMID: 32168750)
Oncotarget. 2018 Apr 27;9(32):22665-22679. (PMID: 29854306)
Cell Rep. 2019 Jan 15;26(3):608-623.e6. (PMID: 30650355)
Cell Tissue Res. 2018 May;372(2):233-243. (PMID: 28924803)
Sci Adv. 2022 Oct 28;8(43):eabq4617. (PMID: 36306349)
Arch Med Sci. 2018 Jun;14(4):910-919. (PMID: 30002710)
Molecules. 2020 Feb 10;25(3):. (PMID: 32050529)
J Pediatr Surg. 2016 Feb;51(2):285-8. (PMID: 26651282)
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18632-7. (PMID: 24167277)
Cancer Chemother Pharmacol. 1989;24(3):148-54. (PMID: 2544306)
JAMA Oncol. 2021 Apr 01;7(4):525-533. (PMID: 33630025)
Cancer Res. 2018 Oct 15;78(20):5958-5969. (PMID: 30154149)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
Adv Pediatr. 2011;58(1):297-311. (PMID: 21736987)
Cancers (Basel). 2021 Jun 26;13(13):. (PMID: 34206917)
Nat Mater. 2022 Feb;21(2):143-159. (PMID: 34385685)
Cancer Res. 2021 Dec 1;81(23):5818-5832. (PMID: 34610968)
Front Immunol. 2021 Jun 29;12:689697. (PMID: 34267756)
Transl Oncol. 2021 Jul;14(7):101099. (PMID: 33887553)
Sci Rep. 2019 Sep 13;9(1):13259. (PMID: 31519958)
Pediatr Blood Cancer. 2011 Jan;56(1):50-7. (PMID: 21108439)
Cancers (Basel). 2022 Feb 01;14(3):. (PMID: 35159029)
Sci Adv. 2021 Aug 18;7(34):. (PMID: 34407932)
Biofabrication. 2022 Apr 12;14(3):. (PMID: 35333193)
Cancer Discov. 2018 Sep;8(9):1096-1111. (PMID: 29903880)
Cells. 2019 Aug 05;8(8):. (PMID: 31387210)
Int J Bioprint. 2021 Oct 21;7(4):444. (PMID: 34805601)
J Pediatr Surg. 2021 Jun;56(6):1165-1173. (PMID: 33762121)
ACS Appl Bio Mater. 2020 Sep 21;3(9):5552-5573. (PMID: 35021789)
Nat Rev Cancer. 2004 Jun;4(6):437-47. (PMID: 15170446)
Front Oncol. 2013 Jan 22;3:2. (PMID: 23346552)
Polymers (Basel). 2022 Sep 28;14(19):. (PMID: 36236019)
Nat Commun. 2020 Jul 22;11(1):3669. (PMID: 32699356)
Eur J Cancer. 2019 May;112:49-56. (PMID: 30928805)
J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33757986)
Adv Sci (Weinh). 2022 Aug;9(23):e2200244. (PMID: 35644929)
Curr Protoc Pharmacol. 2013 Jun;Chapter 14:Unit 14.25. (PMID: 23744710)
EBioMedicine. 2020 Jan;51:102624. (PMID: 31923800)
Cancer Cell. 2020 Nov 9;38(5):716-733.e6. (PMID: 32946775)
Adv Healthc Mater. 2022 Jun;11(11):e2102097. (PMID: 35114074)
Cell Res. 2020 Oct;30(10):833-853. (PMID: 32499560)
Nat Genet. 2019 Feb;51(2):308-318. (PMID: 30643250)
Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41. (PMID: 11395851)
معلومات مُعتمدة: T32 CA229102 United States CA NCI NIH HHS; U01 CA223976 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: 3D bioprinting; Neuroblastoma; Neuroendocrine; Patient-derived xenografts; Pediatrics; Targeted therapy
تواريخ الأحداث: Date Created: 20230616 Latest Revision: 20240828
رمز التحديث: 20240828
مُعرف محوري في PubMed: PMC10261178
DOI: 10.18063/ijb.723
PMID: 37323483
قاعدة البيانات: MEDLINE
الوصف
تدمد:2424-8002
DOI:10.18063/ijb.723